Abstract
Aim. To study the impact of combined therapy with the angiotensin-converting enzyme inhibitor enap and the calcium antagonist corinfar SR on the values of blood pressure (BP) and the content of lipid peroxidation products in patients with.arterial hypertension (AH). Subjects and methods. Twenty-eight patients with Stage I-IIAH were treated with a combination of enap and corinfar SR for 6 weeks in the outpatient setting. The time course of changes in BP and the serum levels of dienic conjugates and malonic dialdehyde were determined. Results. The effective therapy with a combination of enap and corinfar SR was possible in 83% of the patients. Systolic and diastolic BPs decreased by 24 and 21% and they were 135,1±8,3 and 84,1±4,3 mm Hg, respectively. The content of dienic conjugates and malonic dialdehyde reduced by 10 and 9%, respectively. Conclusion. In addition to a steady-state BP decrease, 6-week combined therapy with enap and corinfar SR inhibits the serum activity of intermediate lipid peroxidation products.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
